Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice
Open Access
- 10 February 2017
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 6 (3) , e1290035
Abstract
When compared with vascular cells in normal tissues, pericytes and vascular endothelial cells (VEC) in tumor blood vessels exhibit altered morphology and epigenetic programming that leads to the expression of unique antigens that allow for differential recognition by CD8+ T cells. We have previously shown that the Notch antagonist delta-like homolog 1 (DLK1) is a tumor pericyte-associated antigen expressed in setting of melanoma and a range of carcinomas. In this report, we show that therapeutic vaccination against DLK1 in murine models results in slowed tumor growth, but also to the compensatory expression of the DLK1 homolog, DLK2, by tumor-associated pericytes. Vaccines targeting both DLK1 and DLK2 resulted in superior antitumor benefits in association with improved activation and recruitment of antigen-specific Type 1 CD8+ T cells, reduced presence of myeloid-derived suppressive cells, T regulatory cell and tumor vascular normalization. The antitumor efficacy of vaccines coordinately targeting DLK1 and DLK2 was further improved by inclusion of PD-L1 blockade, thus defining a combination immunotherapy theoretically suitable for the treatment of a broad range of solid (vascularized) cancers.Keywords
This publication has 55 references indexed in Scilit:
- Vaccines for established cancer: overcoming the challenges posed by immune evasionNature Reviews Cancer, 2016
- Therapeutic cancer vaccinesJournal of Clinical Investigation, 2015
- Transcriptional regulation by hypoxia inducible factorsCritical Reviews in Biochemistry and Molecular Biology, 2013
- Transcription Factor Klf4, Induced in the Lung by Oxygen at Birth, Regulates Perinatal Fibroblast and Myofibroblast DifferentiationPLOS ONE, 2013
- DLK1, delta-like 1 homolog (Drosophila), regulates tumor cell differentiation in vivoCancer Letters, 2012
- DLK1 as a Potential Target against Cancer Stem/Progenitor Cells of Hepatocellular CarcinomaMolecular Cancer Therapeutics, 2012
- Tim3 binding to galectin-9 stimulates antimicrobial immunityJournal of Experimental Medicine, 2010
- HIF2α inhibition promotes p53 pathway activity, tumor cell death, and radiation responsesProceedings of the National Academy of Sciences, 2009
- Impact of Epitope Escape on PD-1 Expression and CD8 T-Cell Exhaustion during Chronic InfectionJournal of Virology, 2009
- Anti-cancer therapies targeting the tumor stromaCancer Immunology, Immunotherapy, 2007